Question explored with the scientific record
Conversation so far
- 1 What is best treatment for fibromyalgia
- 2 How do pregabalin or duloxetine compare for side effects and benefits?
Answered on this page ↓
How do pregabalin or duloxetine compare for side effects and benefits?
Neither is a strong drug for fibromyalgia. Both work better than placebo but the gap is small, and side effects are common enough that many people stop them.
The evidence for both drugs comes mostly from manufacturer-funded trials that last 8 to 15 weeks. No trial compared the two head-to-head in a way that picks a clear winner, so the comparison is indirect.
Pregabalin. Pooled data from three trials with 1,122 patients found that pregabalin 600 mg/day produced at least 50% pain relief in 24% of patients, versus 15% on placebo [4]. That is a number needed to treat of 11. The number needed to harm was 5.9, meaning dizziness, drowsiness, or weight gain was common enough that one in every six people had a side effect that mattered [4]. Sleep improved faster than pain—often within two days—but the effect was on sleep quality, not pain intensity [1, 3].
Duloxetine at 60 mg per day works similarly. In six placebo-controlled trials pooled in a Cochrane review, it was effective for pain at 12 weeks, but the effect was small enough that the number needed to treat for a 50% pain reduction was about 7 [5]. Nausea, insomnia, and dry mouth were the main side effects, and the dropout rate for duloxetine was higher than placebo [7, 8]. At 120 mg the side effects were worse with no extra benefit.
Direct comparison from the evidence: A 2024 trial in 156 fibromyalgia patients compared duloxetine 60 mg to amitriptyline 12.5–25 mg, not to pregabalin, and found amitriptyline scored better on the WPI and SSS at 12 weeks [9]. The combination of pregabalin plus duloxetine in a 2016 RCT worked better for pain (average pain score 3.7 vs 5.0 on pregabalin alone and 4.1 on duloxetine alone), but side effects added up since both drug classes were needed [2].
The real limitation is that none of these trials ran longer than 3 to 6 months. Fibromyalgia is a chronic condition. The same drug at the same dose is less effective over time as the body adapts, and the long-term safety data on both drugs comes from open-label extensions where everyone knew they were on the drug, which inflates the apparent benefit [6]. A 2022 review in Rheumatology concluded the cumulative effect of either drug is small [5].
My call: neither drug is clearly better for fibromyalgia. Pregabalin helps sleep faster, duloxetine gives slightly better pain scores, but both have side effects that cause many people to stop. Try one, and if it does not show clear benefit within 4 weeks, stop it and try the other; combination is a third option if each alone helped a little.
Confidence: moderate. The trials are consistent but short, manufacturer-funded, and show only small effects.
Sources used 9
-
Time to Improvement of Pain and Sleep Quality in Clinical Trials of Pregabalin for the Treatment of Fibromyalgia
This study investigates the time to immediate and sustained clinical improvement in pain and sleep quality in fibromyalgia patients treated with pregabalin, revealing that significant improvements occur within 1-2 days of treatment initiation compared to placebo.
DOI: 10.1111/pme.12636 -
Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial
This randomized controlled trial investigates the efficacy of a pregabalin-duloxetine combination compared to monotherapy in reducing pain and improving quality of life in fibromyalgia patients, demonstrating significant benefits for the combination treatment.
DOI: 10.1097/j.pain.0000000000000558 -
A review of the effects of pregabalin on sleep disturbance across multiple clinical conditions
A comprehensive review synthesizing evidence that pregabalin improves sleep disturbance across multiple clinical conditions (neuropathic pain, fibromyalgia, restless legs syndrome, epilepsy, generalized anxiety disorder, and more), with polysomnography and patient-reported outco…
DOI: 10.1016/j.smrv.2013.07.005 -
Meta-analysis on the Role of Pregabalin in Fibromyalgia
Pregabalin monotherapy reduces fibromyalgia pain in adults, with fixed- and titrated-dose regimens showing significant improvements over placebo and a generally favorable safety profile.
DOI: 10.65564/pjim.10e3a93bbd -
Fibromyalgia syndrome: epidemiology, diagnosis and treatment
Fibromyalgia syndrome is a common chronic pain disorder with evolving diagnostic criteria and multimodal management integrating drugs like pregabalin and duloxetine with exercise, CBT, and education.
DOI: 10.5114/reum.2022.123671 -
Long-term safety and tolerability of pregabalin treatment in three open-label extension studies in patients with fibromyalgia
A pooled analysis of pregabalin trials in fibromyalgia shows meaningful improvements in fatigue, function, and self-reported presenteeism at 450 mg/day, with supportive long-term safety data from open-label extensions, and supplementary analyses on milnacipran's PGIC relationshi…
DOI: 10.1016/j.jpain.2009.01.303 -
Flexible Dosed Duloxetine in the Treatment of Fibromyalgia: A Randomized, Double-blind, Placebo-controlled Trial
This study investigates the efficacy of flexible doses of duloxetine (60-120 mg/day) in improving fibromyalgia symptoms over a 24-week period, demonstrating significant improvements in patient-reported outcomes compared to placebo.
DOI: 10.3899/jrheum.100365 -
Pharmacotherapy of Fibromyalgia: Focus on Duloxetine
This narrative review concludes that duloxetine is efficacious and safe for fibromyalgia, supported by placebo-controlled trials and meta-analyses, and recommends starting low and titrating slowly within multimodal therapy.
DOI: 10.4137/cmt.s1162 -
Comparison of Efficacy of Duloxetine Versus Amitriptyline in Fibromyalgia Patients
In 156 fibromyalgia patients, a 12-week comparative trial found significantly lower WPI and SSS scores and larger percentage reductions with amitriptyline than with duloxetine; the authors concluded amitriptyline was superior.
DOI: 10.55279/jafmdc.v6i2.280